Picture loading failed.

Anti-CD79B therapeutic antibody (Pre-made Iladatuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ladiratuzumab vedotin, also known as SGN-LIV1A and anti-LIV-1 ADC, is a humanized antibody conjugated through a proteolytically cleavable linker to MMAE to Zinc transporter LIV-1 (SLC39A6).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-264-1mg 1mg Inquiry
GMP-Bios-ab-264-10mg 10mg Inquiry
GMP-Bios-ab-264-100mg 100mg Inquiry
GMP-Bios-ab-264-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD79B therapeutic antibody (Pre-made Iladatuzumab biosimilar,Whole mAb ADC)
INN Name Iladatuzumab
TargetCD79B
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2019
CompaniesRoche
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedNon-Hodgkin's lymphoma
Development Techna